Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) EBITDA Margin (2020 - 2022)

Historic EBITDA Margin for Therapeutics (RAPT) over the last 3 years, with Q2 2022 value amounting to 2123.25%.

  • Therapeutics' EBITDA Margin fell 2753800.0% to 2123.25% in Q2 2022 from the same period last year, while for Mar 2023 it was 10291.76%, marking a year-over-year decrease of 79995000.0%. This contributed to the annual value of 5478.59% for FY2022, which is 36628800.0% down from last year.
  • As of Q2 2022, Therapeutics' EBITDA Margin stood at 2123.25%, which was down 2753800.0% from 3335.26% recorded in Q1 2022.
  • Over the past 5 years, Therapeutics' EBITDA Margin peaked at 956.7% during Q2 2020, and registered a low of 3335.26% during Q1 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 1627.25% (2020), whereas its average is 1730.04%.
  • As far as peak fluctuations go, Therapeutics' EBITDA Margin soared by 542600bps in 2021, and later crashed by -19828800bps in 2022.
  • Therapeutics' EBITDA Margin (Quarter) stood at 997.39% in 2020, then plummeted by -141bps to 2404.76% in 2021, then increased by 12bps to 2123.25% in 2022.
  • Its EBITDA Margin stands at 2123.25% for Q2 2022, versus 3335.26% for Q1 2022 and 2404.76% for Q4 2021.